Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind study of glycopyrronium bromide add-on therapy in poorly controlled asthma
2013-002664-10Phase 3Terminated
- Sponsor
- Novartis
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Glycopyrronium bromide 50 µg o.d. + LABA/ICS with Placebo + LABA/ICS (2 arms). Primary endpoint: Trough FEV1 at Week 26. Started Jan 2014; status: terminated.
02
Drugs
glycopyrronium
03
Conditions
asthma
Beyond the preview
Go deeper on 2013-002664-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002664-10.